Breaking News Instant updates and real-time market news.

AMGN

Amgen

$185.48

1.79 (0.97%)

, MYL

Mylan

$38.48

-0.36 (-0.93%)

17:15
06/04/18
06/04
17:15
06/04/18
17:15

FDA approves first biosimilar to Neulasta

The U.S. Food and Drug Administration today approved Fulphila, pegfilgrastim-jmdb, as the first biosimilar to Neulasta to decrease the chance of infection as suggested by febrile neutropeniafever, often with other signs of infection, associated with an abnormally low number of infection-fighting white blood cells, in patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence of febrile neutropenia.The FDA granted approval of Fulphila to Mylan GmbH (MYL). Neulasta is made by Amgen (AMGN).

AMGN

Amgen

$185.48

1.79 (0.97%)

MYL

Mylan

$38.48

-0.36 (-0.93%)

  • 04

    Jun

  • 13

    Nov

AMGN Amgen
$185.48

1.79 (0.97%)

05/17/18
PIPR
05/17/18
NO CHANGE
Target $190
PIPR
Overweight
Amgen's Aimovig launch in migraine should beat expectations, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $190 price target on Amgen (AMGN) after today's FDA approval of Aimovig in migraine. The analyst notes that this marks the first anti-CGRP therapy approval in what is expected to be a crowded space, adding that Amgen and its partner Novartis (NVS) have "effectively capitalized on their first-mover advantage." The analyst says the smart pricing for the product should allow this launch to "beat expectations".
05/18/18
WELS
05/18/18
NO CHANGE
WELS
Amgen migraine drug price may be below expectations, says Wells Fargo
The FDA, as expected, approved Amgen (AMGN) and Novartis' (NVS) first-in-class anti-CGRP treatment Aimovig for the prevention of migraine, Wells Fargo analyst David Maris tells investors in a research note. The only part of the news which may be somewhat unexpected could be the pricing, which came in at $575 per month or $6,900 annually, the analyst adds. He thinks some investors may have been expecting the price in the $12,000 range. Maris thinks there may be a potential negative read-through on the pricing for Teva (TEVA) and to a lesser extent, Allergan (AGN).
05/18/18
CANT
05/18/18
NO CHANGE
Target $18
CANT
Neutral
Amgen approval in migraine positive for Teva, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen thinks FDA approval of Amgen's (AMGN) Aimovig is positive for Teva (TEVA) as well as other new potential migraine treatments coming to the market because it underscores the large unmet need. She notes, however, that Teva does not expect approval until later this year given its manufacturing issues. The analyst keeps a Neutral rating on Teva with an $18 price target.
05/18/18
JEFF
05/18/18
NO CHANGE
Target $200
JEFF
Buy
Amgen price for Aimovig lower than expected, says Jefferies
Jefferies analyst Michael Yee says the confirmed list price of $6,900 for Amgen's (AMGN) Aimovig is lower than Street expectations of $7,000-$10,000. The analyst thinks the net price could fall to around $5,000-$6,000 as Allergan's (AGN) Botox is around $6,000. Amgen's pricing strategy sends a good message and fits well into the current reimbursement environment, Yee tells investors in a research note. He keeps a Buy rating on the shares with a $200 price target.
MYL Mylan
$38.48

-0.36 (-0.93%)

04/25/18
WELS
04/25/18
NO CHANGE
WELS
Market Perform
Glaxo comments on Advair have negative read through for Mylan, says Wells Fargo
Noting that GlaxoSmithKline (GSK) said it now expects branded Advair sales to decline 30% this year, even excluding the impact of a generic, Wells Fargo analyst David Maris said the news has a negative read through for Mylan (MYL) given that its generic Advair is one of the company's highest profile pipeline items. While Advair will be a good generic opportunity, it represents "a fraction of what some might have previously believed," said Maris, who has a Market Perform rating on Mylan shares.
05/15/18
MZHO
05/15/18
UPGRADE
Target $27
MZHO
Buy
Mizuho compares Valeant portfolio to Mylan in upgrade to Buy
Mizuho analyst Irina Koffler upgraded Valeant Pharmaceuticals (VRX) to Buy from Neutral and raised her price target for the shares to $27 from $15. The stock closed yesterday down 4c to $20.81. Adjusting individual product growth estimates has made the analyst more constructive on Valeant's turnaround story. The company's portfolio now looks Mylan-like (MYL) in that 70% of revenue consists of stable products that are either consumer-focused, or older drugs that are already generic, Koffler tells investors in a research note. Further, the analyst sees growth potential from Valeant's pipeline, which she notes contains multiple catalysts in 2018-2020 and is not in her estimates. She thinks that in order for the stock to work over the next year, Valeant just needs to execute on its quarters and push through new product launches.
05/18/18
BERN
05/18/18
NO CHANGE
Target $54
BERN
Outperform
Biocon 483 letter won't delay approval of Mylan's Neulasta, says Bernstein
Bernstein analyst Aaron Gal said that the 483 letter for Biocon's Bangalore facility contains seven observations, all related to cleaning procedures, and does not contain any argument of systemic or recurring problem, suggestions of any of the procedure deviations creating patient risk or problems requiring changes in the facility structure or equipment. In a research note to investors, Gal said the 483 is viewed as being on the "lighter side," and can be "reasonably" addressed through change in procedure, and does not believe it will delay the tentative approval of Biocon/Mylan's Neulasta. The analyst has an Outperform rating and $54 price target on Mylan.
05/23/18
JPMS
05/23/18
NO CHANGE
Target $53
JPMS
Overweight
Mylan risk/reward favorable into June catalysts, says JPMorgan
JPMorgan analyst Chris Schott sees a favorable setup and risk/reward for Mylan shares heading into June. His downside case, in which biosimilar Neulasta, generic Advair and generic Restasis do not get approved in 2018, supports earnings per share in the low $5 range and a stock that he struggles to see sustainably below the mid $30's. The analyst's upside case, which has some mix of Advair, Neulasta and Restasis approved, supports a share price "well above" $50. Looking beyond near-term catalysts, Schott believes Mylan is "very well-positioned" within the generics space. He keeps an Overweight rating on the shares with a $53 price target.

TODAY'S FREE FLY STORIES

BHLB

Berkshire Hills Bancorp

$40.80

0.15 (0.37%)

22:34
07/18/18
07/18
22:34
07/18/18
22:34
Upgrade
Berkshire Hills Bancorp rating change  »

Berkshire Hills Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

PG

Procter & Gamble

$79.71

-0.34 (-0.42%)

22:34
07/18/18
07/18
22:34
07/18/18
22:34
Downgrade
Procter & Gamble rating change  »

Procter & Gamble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

GWW

Grainger

$338.99

33.78 (11.07%)

22:33
07/18/18
07/18
22:33
07/18/18
22:33
Upgrade
Grainger rating change  »

Grainger upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

MS

Morgan Stanley

$50.54

1.34 (2.72%)

22:32
07/18/18
07/18
22:32
07/18/18
22:32
Upgrade
Morgan Stanley rating change  »

Morgan Stanley upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

ESTA

Establishment Labs

$0.00

(0.00%)

22:17
07/18/18
07/18
22:17
07/18/18
22:17
Syndicate
Establishment Labs 3.715M share IPO priced at $18.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

CNST

Constellation Pharmaceuticals

$0.00

(0.00%)

22:12
07/18/18
07/18
22:12
07/18/18
22:12
Syndicate
Constellation Pharmaceuticals 4M share IPO priced at $15.00 »

The deal size was reduced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

CARB

Carbonite

$37.90

0.6 (1.61%)

22:09
07/18/18
07/18
22:09
07/18/18
22:09
Syndicate
Carbonite 5.463M share Secondary priced at $37.50 »

The company increased the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 02

    Aug

  • 16

    Aug

  • 19

    Jul

TLRY

Tilray

$0.00

(0.00%)

22:04
07/18/18
07/18
22:04
07/18/18
22:04
Syndicate
Tilray 9M share IPO priced at $17.00 »

The deal range was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

JBLU

JetBlue

$19.97

0.44 (2.25%)

, EADSY

Airbus

$0.00

(0.00%)

20:47
07/18/18
07/18
20:47
07/18/18
20:47
Periodicals
JetBlue founder to launch new U.S. low-cost airline, LA Times says »

JetBlue (JBLU) founder…

JBLU

JetBlue

$19.97

0.44 (2.25%)

EADSY

Airbus

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

PTC

PTC

$98.51

-0.4 (-0.40%)

20:28
07/18/18
07/18
20:28
07/18/18
20:28
Recommendations
PTC analyst commentary at MUFG »

PTC price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

PM

Philip Morris

$82.16

-0.17 (-0.21%)

, UNP

Union Pacific

$141.26

2.96 (2.14%)

20:25
07/18/18
07/18
20:25
07/18/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

PM

Philip Morris

$82.16

-0.17 (-0.21%)

UNP

Union Pacific

$141.26

2.96 (2.14%)

DHR

Danaher

$98.80

-0.78 (-0.78%)

BK

BNY Mellon

$55.64

1.59 (2.94%)

BX

Blackstone

$36.23

0.52 (1.46%)

BBT

BB&T

$52.99

1 (1.92%)

TRV

Travelers

$130.03

1.26 (0.98%)

PPG

PPG

$106.84

1.43 (1.36%)

KEY

KeyCorp

$20.30

0.24 (1.20%)

FITB

Fifth Third

$30.26

0.75 (2.54%)

NUE

Nucor

$65.65

1.045 (1.62%)

GPC

Genuine Parts

$94.64

0.47 (0.50%)

ADS

Alliance Data

$226.51

1.13 (0.50%)

DPZ

Domino's Pizza

$283.74

1.74 (0.62%)

DOV

Dover

$74.21

-0.37 (-0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 08

    Aug

  • 26

    Aug

  • 21

    Sep

  • 05

    Oct

  • 30

    Oct

FFKT

Farmers Capital Bank

$53.50

0.65 (1.23%)

20:23
07/18/18
07/18
20:23
07/18/18
20:23
Earnings
Farmers Capital Bank reports Q2 EPS 83c, consensus 73c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APC

Anadarko

$71.49

0.06 (0.08%)

20:13
07/18/18
07/18
20:13
07/18/18
20:13
Recommendations
Anadarko analyst commentary at MUFG »

Anadarko price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

HES

Hess Corp.

$64.14

0.67 (1.06%)

20:00
07/18/18
07/18
20:00
07/18/18
20:00
Recommendations
Hess Corp. analyst commentary at MUFG »

Hess Corp price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

NBL

Noble Energy

$34.34

-0.11 (-0.32%)

19:52
07/18/18
07/18
19:52
07/18/18
19:52
Recommendations
Noble Energy analyst commentary at MUFG »

Noble Energy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

NDLS

Noodles & Company

$11.80

-0.35 (-2.88%)

, IBM

IBM

$144.44

0.98 (0.68%)

19:08
07/18/18
07/18
19:08
07/18/18
19:08
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

NDLS

Noodles & Company

$11.80

-0.35 (-2.88%)

IBM

IBM

$144.44

0.98 (0.68%)

BHLB

Berkshire Hills Bancorp

$40.80

0.15 (0.37%)

CL

Colgate-Palmolive

$64.81

-0.76 (-1.16%)

EGAN

eGain

$13.15

-0.75 (-5.40%)

EBAY

eBay

$37.95

0.13 (0.34%)

CCK

Crown Holdings

$45.12

-0.265 (-0.58%)

PTC

PTC

$98.51

-0.4 (-0.40%)

AXP

American Express

$102.98

1.84 (1.82%)

URI

United Rentals

$155.14

2.94 (1.93%)

AA

Alcoa

$47.90

-0.105 (-0.22%)

SPWH

Sportsman's Warehouse

$5.23

-0.16 (-2.97%)

RUN

Sunrun

$15.16

-0.02 (-0.13%)

CLX

Clorox

$129.50

-5.5 (-4.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 27

    Jul

  • 02

    Aug

  • 06

    Aug

  • 08

    Aug

  • 09

    Aug

  • 19

    Jul

GSBC

Great Southern Bancorp

$58.55

-0.2 (-0.34%)

19:03
07/18/18
07/18
19:03
07/18/18
19:03
Earnings
Great Southern Bancorp reports Q2 EPS 97c, consensus 94c »

Reports Q2 NII $41.2M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMAB

OMA Airports

$45.82

-0.48 (-1.04%)

18:40
07/18/18
07/18
18:40
07/18/18
18:40
Hot Stocks
OMA Airports reports Q2 passenger traffic up 9.6% »

OMA generated a 25.7%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OPTN

Optinose

$26.97

0.36 (1.35%)

18:35
07/18/18
07/18
18:35
07/18/18
18:35
Recommendations
Optinose analyst commentary at BMO Capital »

Optinose's Xhance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$31.73

-0.02 (-0.06%)

18:29
07/18/18
07/18
18:29
07/18/18
18:29
Periodicals
DOJ: AT&T-Time Warner ruling ignored 'basic economics,' FT reports »

The U.S. Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 09

    Aug

SBGI

Sinclair Broadcast

$27.35

-0.65 (-2.32%)

, TRCO

Tribune Media

$34.09

0.79 (2.37%)

18:26
07/18/18
07/18
18:26
07/18/18
18:26
Hot Stocks
FCC votes unanimously to adopt hearing order on Sinclair-Tribune deal »

This evening, the Federal…

SBGI

Sinclair Broadcast

$27.35

-0.65 (-2.32%)

TRCO

Tribune Media

$34.09

0.79 (2.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 06

    Sep

RUN

Sunrun

$15.16

-0.02 (-0.13%)

, JKS

JinkoSolar

$13.70

-0.1 (-0.72%)

18:25
07/18/18
07/18
18:25
07/18/18
18:25
Downgrade
Sunrun, JinkoSolar, Canadian Solar, Vivint Solar rating change at Goldman Sachs »

Sunrun downgraded to…

RUN

Sunrun

$15.16

-0.02 (-0.13%)

JKS

JinkoSolar

$13.70

-0.1 (-0.72%)

CSIQ

Canadian Solar

$12.83

0.15 (1.18%)

VSLR

Vivint Solar

$5.20

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 09

    Aug

SBGI

Sinclair Broadcast

$27.35

-0.65 (-2.32%)

, TRCO

Tribune Media

$34.09

0.79 (2.37%)

18:25
07/18/18
07/18
18:25
07/18/18
18:25
Periodicals
Breaking Periodicals news story on Sinclair Broadcast, Tribune Media »

FCC votes unanimously to…

SBGI

Sinclair Broadcast

$27.35

-0.65 (-2.32%)

TRCO

Tribune Media

$34.09

0.79 (2.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 06

    Sep

RUN

Sunrun

$15.16

-0.02 (-0.13%)

18:13
07/18/18
07/18
18:13
07/18/18
18:13
Downgrade
Sunrun rating change at Goldman Sachs »

Sunrun downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

UNH

UnitedHealth

$255.43

5.11 (2.04%)

, THC

Tenet

$34.57

-0.37 (-1.06%)

18:09
07/18/18
07/18
18:09
07/18/18
18:09
Periodicals
UnitedHealth among suitors eyeing Tenet's Conifer unit, WSJ reports »

UnitedHealth (UNH) is…

UNH

UnitedHealth

$255.43

5.11 (2.04%)

THC

Tenet

$34.57

-0.37 (-1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.